Annexon, Inc. (ANNX) stock
ANNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.57−0.35 (-8.93%)
Close on Nov 16, 2026Market cap $729.87MP/E –Yield 0.00%
Annexon total assets
Total assets on the balance sheet at the end of each period.
Annexon's total assets was $246.07M at Jun 30, 2026. For fiscal 2025 it was $277.57M, down 20.7% from the year before. The highest annual figure on record is $355.95M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $277.57M | -20.7% |
| FY2024 | Dec 31, 2024 | $350.07M | +17.6% |
| FY2023 | Dec 31, 2023 | $297.67M | +4.4% |
| FY2022 | Dec 31, 2022 | $285.10M | -0.7% |
| FY2021 | Dec 31, 2021 | $287.04M | -19.4% |
| FY2020 | Dec 31, 2020 | $355.95M | +613.3% |
| FY2019 | Dec 31, 2019 | $49.90M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $246.07M | -7.0% |
| Q1 FY2026 | Mar 31, 2026 | $262.89M | -13.2% |
| Q4 FY2025 | Dec 31, 2025 | $277.57M | -20.7% |
| Q3 FY2025 | Sep 30, 2025 | $229.14M | -39.5% |
| Q2 FY2025 | Jun 30, 2025 | $264.57M | -34.8% |
| Q1 FY2025 | Mar 31, 2025 | $303.03M | -0.3% |
| Q4 FY2024 | Dec 31, 2024 | $350.07M | +17.6% |
| Q3 FY2024 | Sep 30, 2024 | $378.78M | +85.8% |
| Q2 FY2024 | Jun 30, 2024 | $406.09M | +74.3% |
| Q1 FY2024 | Mar 31, 2024 | $304.07M | +13.1% |
| Q4 FY2023 | Dec 31, 2023 | $297.67M | +4.4% |
| Q3 FY2023 | Sep 30, 2023 | $203.82M | -34.8% |
| Q2 FY2023 | Jun 30, 2023 | $233.01M | +5.6% |
| Q1 FY2023 | Mar 31, 2023 | $268.78M | +7.3% |
| Q4 FY2022 | Dec 31, 2022 | $285.10M | -0.7% |
| Q3 FY2022 | Sep 30, 2022 | $312.72M | +0.8% |
| Q2 FY2022 | Jun 30, 2022 | $220.70M | -33.5% |
| Q1 FY2022 | Mar 31, 2022 | $250.57M | -24.8% |
| Q4 FY2021 | Dec 31, 2021 | $287.04M | -19.4% |
| Q3 FY2021 | Sep 30, 2021 | $310.16M | -17.4% |
| Q2 FY2021 | Jun 30, 2021 | $331.78M | +153.1% |
| Q1 FY2021 | Mar 31, 2021 | $333.12M | +567.6% |
| Q4 FY2020 | Dec 31, 2020 | $355.95M | – |
| Q3 FY2020 | Sep 30, 2020 | $375.61M | – |
| Q2 FY2020 | Jun 30, 2020 | $131.09M | – |
| Q4 FY2019 | Dec 31, 2019 | $49.90M | – |
See a number that looks wrong?